This chart shows claim settlement ratio of life insurance companies... Read On
- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- The 5 Minute WrapUp
- Chart Of The Day
- US opportunity beckons for Indian Pharma
US opportunity beckons for Indian Pharma
Sep 12, 2014
The next few years present a huge opportunity for Indian pharma companies in terms of drugs going off patent in the US market. Patents of drugs worth around US$ 92 bn in sales are expected to expire in the period 2014-16. This is much higher than US$ 65 bn worth of drugs that had gone off patent in 2010-12. Many of these opportunities, especially in 2014, are blockbuster drugs. These are essentially drugs whose annual sales exceed US$ 1 bn. However, while the opportunities are huge there are also challenges.
The US generics market is highly competitive. Especially for blockbuster drugs, because so many players vie for a share of the drug's pie, prices erode considerably. And so the revenue and profit potential also dramatically reduces. That is why quite a few of the big players such as Sun Pharma, Dr.Reddy's and Lupin among others are focusing on building a niche portfolio. This means that they are focusing on drugs which are not easy to manufacture and hence the competition and thereby price erosion is considerably lesser. The other bigger challenge for Indian Pharma is the US FDA. Indeed, the US regulator has become very stringent in terms of maintaining quality at plants. And most domestic pharma companies have been pulled up for not complying with these standards. That is why even if the opportunity exists, it will not amount to much if the standards of the US FDA are not met.
Data Source: Mint
This Chart Of The Day was published in The 5 Minute WrapUp - Are We On The Threshold Of A Mega Returns Opportunity?
Equitymaster requests your view! Post a comment on "US opportunity beckons for Indian Pharma". Click here!
1 Responses to "US opportunity beckons for Indian Pharma"
Equitymaster requests your view! Post a comment on "US opportunity beckons for Indian Pharma". Click here!
Our Most Popular Charts
This chart shows the top 5 countries in terms of improvement in HDI over past 2 decades... Read On
-equitymaster.gif "The top 10 year multibagger stocks")
The chart shows the top 20 multibagger stocks over the past decade.... Read On
This chart shows the persistency rate of insurance policies.... Read On
Market Indices are touching a record high. Time to tread cautiously.... Read On
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
amarish shah
Sep 12, 2014still much cheap share are available in pharam.even us will not support us india market is big.
one example i am giving .if there are 5 cr diabetic patients and they pays only rs. 10.00 per day. the total volume of year of diabetic drugs will be rs.18000.00 cr .
image of others.